Novel glutamatergic drugs for the treatment of mood disorders

References

• CollinsPYPatelVJoestlSSGrand challenges in global mental healthNature20114757354273021734685
   PubMed Web of Science ®Google Scholar
• TrivediMHRushAJWisniewskiSRSTAR*D Study TeamEvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceAm J Psychiatry20061631284016390886
   PubMed Web of Science ®Google Scholar
• FavaMDavidsonKGDefinition and epidemiology of treatment-resistant depressionPsychiatr Clin North Am19961921792008827185
   PubMed Web of Science ®Google Scholar
• RushAJWisniewskiSRZisookSIs prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D reportPsychol Med20124261131114922008447
   PubMed Web of Science ®Google Scholar
• RushAJTrivediMHWisniewskiSRAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportAm J Psychiatry2006163111905191717074942
   PubMed Web of Science ®Google Scholar
• JuddLLAkiskalHSSchettlerPJA prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorderArch Gen Psychiatry200360326126912622659
   PubMed Web of Science ®Google Scholar
• NierenbergAAOstacherMJCalabreseJRTreatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidoneAm J Psychiatry2006163221021616449473
   PubMed Web of Science ®Google Scholar
• KrishnanVNestlerEJLinking molecules to mood: new insight into the biology of depressionAm J Psychiatry2010167111305132020843874
   PubMed Web of Science ®Google Scholar
• MillerGIs pharma running out of brainy ideas?Science2010329599150250420671165
   PubMed Web of Science ®Google Scholar
• OrregoFVillanuevaSThe chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localizationNeuroscience19935635395557902967
   PubMed Web of Science ®Google Scholar
• HashimotoKSawaAIyoMIncreased levels of glutamate in brains from patients with mood disordersBiol Psychiatry200762111310131617574216
   PubMed Web of Science ®Google Scholar
• AuerDPPützBKraftELipinskiBSchillJHolsboerFReduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy studyBiol Psychiatry200047430531310686265
   PubMed Web of Science ®Google Scholar
• SanacoraGGueorguievaREppersonCNSubtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depressionArch Gen Psychiatry200461770571315237082
   PubMed Web of Science ®Google Scholar
• HashimotoKEmerging role of glutamate in the pathophysiology of major depressive disorderBrain Res Rev200961210512319481572
   PubMed Web of Science ®Google Scholar
• BeneytoMKristiansenLVOni-OrisanAMcCullumsmithREMeador-WoodruffJHAbnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disordersNeuropsychopharmacology20073291888190217299517
   PubMed Web of Science ®Google Scholar
• PaulIANowakGLayerRTPopikPSkolnickPAdaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatmentsJ Pharmacol Exp Ther19942691951028169857
   PubMed Web of Science ®Google Scholar
• MathewsDCHenterIDZarateCATargeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateDrugs201272101313133322731961
   PubMed Web of Science ®Google Scholar
• MusazziLTreccaniGMalleiAPopoliMThe action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptorsBiol Psychiatry201373121180118823273725
   PubMed Web of Science ®Google Scholar
• SerafiniGPompiliMInnamoratiMDwivediYBrahmachariGGirardiPPharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depressionCurr Pharm Des201319101898192223173582
   PubMed Web of Science ®Google Scholar
• GreenSMJohnsonNEKetamine sedation for pediatric procedures: Part 2, Review and implicationsAnn Emerg Med1990199103310462203290
   PubMed Web of Science ®Google Scholar
• BermanRMCappielloAAnandAAntidepressant effects of ketamine in depressed patientsBiol Psychiatry200047435135410686270
   PubMed Web of Science ®Google Scholar
• ZarateCAJrSinghJBCarlsonPJA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depressionArch Gen Psychiatry200663885686416894061
   PubMed Web of Science ®Google Scholar
• MathewSJMurroughJWaan het RotMCollinsKAReichDLCharneyDSRiluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trialInt J Neuropsychopharmacol2010131718219288975
   PubMed Web of Science ®Google Scholar
• aan het RotMCollinsKAMurroughJWSafety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depressionBiol Psychiatry201067213914519897179
   PubMed Web of Science ®Google Scholar
• MurroughJWPerezAMMathewSJCharneyDSA case of sustained remission following an acute course of ketamine in treatment-resistant depressionJ Clin Psychiatry201172341441521450159
   PubMed Web of Science ®Google Scholar
• DiazgranadosNIbrahimLBrutscheNEA randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depressionArch Gen Psychiatry201067879380220679587
   PubMed Web of Science ®Google Scholar
• ZarateCAJrBrutscheNEIbrahimLReplication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trialBiol Psychiatry2012711193994622297150
   PubMed Web of Science ®Google Scholar
• IbrahimLDiazgranadosNFranco-ChavesJCourse of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled studyNeuropsychopharmacology20123761526153322298121
   PubMed Web of Science ®Google Scholar
• MurroughJWPerezAMPillemerSRapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depressionBiol Psychiatry EpubJuly262012
   Web of Science ®Google Scholar
• MorganCJMuetzelfeldtLCurranHVKetamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and exusers with polydrug and non-using controlsAddiction20091041778719133891
   PubMed Web of Science ®Google Scholar
• OlneyJWLabruyereJWangGWozniakDFPriceMTSesmaMANMDA antagonist neurotoxicity: mechanism and preventionScience19912545037151515181835799
   PubMed Web of Science ®Google Scholar
• OlneyJWLabruyereJPriceMTPathological changes induced in cerebrocortical neurons by phencyclidine and related drugsScience19892444910136013622660263
   PubMed Web of Science ®Google Scholar
• ManjiHKQuirozJASpornJEnhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depressionBiol Psychiatry200353870774212706957
   PubMed Web of Science ®Google Scholar
• DumanRSAghajanianGKSynaptic dysfunction in depression: potential therapeutic targetsScience20123386103687223042884
   PubMed Web of Science ®Google Scholar
• BensimonGLacomblezLMeiningerVA controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study GroupN Engl J Med199433095855918302340
   PubMed Web of Science ®Google Scholar
• ZarateCAManjiHKRiluzole in psychiatry: a systematic review of the literatureExpert Opin Drug Metab Toxicol2008491223123418721116
   PubMed Web of Science ®Google Scholar
• GourleySLEspitiaJWSanacoraGTaylorJRAntidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in micePsychopharmacology (Berl)2012219380581421779782
   PubMed Web of Science ®Google Scholar
• BanasrMChowdhuryGMTerwilligerRGlial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzoleMol Psychiatry201015550151118825147
   PubMed Web of Science ®Google Scholar
• TakahashiKMurasawaHYamaguchiKRiluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depressionBehav Brain Res20112161465220620171
   PubMed Web of Science ®Google Scholar
• ZarateCAJrPayneJLQuirozJAn open-label trial of riluzole in patients with treatment-resistant major depressionAm J Psychiatry2004161117117414702270
   PubMed Web of Science ®Google Scholar
• BrennanBPHudsonJIJensenJERapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzoleNeuropsychopharmacology201035383484619956089
   PubMed Web of Science ®Google Scholar
• ZarateCAJrQuirozJASinghJBAn open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depressionBiol Psychiatry200557443043215705360
   PubMed Web of Science ®Google Scholar
• SanacoraGKendellSFLevinYPreliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptomsBiol Psychiatry200761682288217141740
   PubMed Web of Science ®Google Scholar
• GrunzeHvon WegererJGreeneRWWaldenJModulation of calcium and potassium currents by lamotrigineNeuropsychobiology19983831311389778600
   PubMed Web of Science ®Google Scholar
• SouthamEKirkbyDHigginsGAHaganRMLamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in ratsEur J Pharmacol1998358119249809864
   PubMed Web of Science ®Google Scholar
• CrumrineRCBergstrandKCooperATFaisonWLCooperBRLamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrestStroke1997281122302236 discussion 22379368570
   PubMed Web of Science ®Google Scholar
• MajRFarielloRGUkmarGPNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the ratEur J Pharmacol1998359127329831289
   PubMed Web of Science ®Google Scholar
• SzymczykGZebrowska-LupinaIInfluence of antiepileptics on efficacy of antidepressant drugs in forced swimming testPol J Pharmacol200052533734411334225
   PubMedGoogle Scholar
• BourinMMasseFHascoëtMEvidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming testJ Psychiatry Neurosci200530427528216049571
   PubMed Web of Science ®Google Scholar
• ConsoniFTVitalMAAndreatiniRDual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming testEur Neuropsychopharmacol200616645145816503122
   PubMed Web of Science ®Google Scholar
• LiNHeXZhangYBrain-derived neurotrophic factor signalling mediates antidepressant effects of lamotrigineInt J Neuropsychopharmacol20111481091109820846461
   PubMed Web of Science ®Google Scholar
• GoodwinGMBowdenCLCalabreseJRA pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorderJ Clin Psychiatry200465343244115096085
   PubMed Web of Science ®Google Scholar
• BowdenCLA placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorderArch Gen Psychiatry200360439240012695317
   PubMed Web of Science ®Google Scholar
• CalabreseJRBowdenCLSachsGLamictal 605 Study GroupA placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorderJ Clin Psychiatry20036491013102414628976
   PubMed Web of Science ®Google Scholar
• CalabreseJRSuppesTBowdenCLA double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study GroupJ Clin Psychiatry2000611184185011105737
   PubMed Web of Science ®Google Scholar
• GabrielALamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive studyDepress Anxiety200623848548816845646
   PubMed Web of Science ®Google Scholar
• SchindlerFAnghelescuIGLithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label studyInt Clin Psychopharmacol200722317918217414745
   PubMed Web of Science ®Google Scholar
• FryeMAKetterTAKimbrellTAA placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disordersJ Clin Psychopharmacol200020660761411106131
   PubMed Web of Science ®Google Scholar
• ObroceaGVDunnRMFryeMAClinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disordersBiol Psychiatry200251325326011839368
   PubMed Web of Science ®Google Scholar
• SantosMARochaFLHaraCEfficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind studyPrim Care Companion J Clin Psychiatry200810318719018615166
   PubMedGoogle Scholar
• BarbosaLBerkMVorsterMA double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodesJ Clin Psychiatry200364440340712716240
   PubMed Web of Science ®Google Scholar
• NormannCHummelBSchärerLOHörnMGrunzeHWaldenJLamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind studyJ Clin Psychiatry200263433734412000208
   PubMed Web of Science ®Google Scholar
• BarbeeJGThompsonTRJamhourNJA double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depressionJ Clin Psychiatry201172101405101221367355
   PubMed Web of Science ®Google Scholar
• KrystalJHSanacoraGBlumbergHGlutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatmentsMol Psychiatry20027Suppl 1S71S8011986998
   PubMed Web of Science ®Google Scholar
• MurroughJWCharneyDSCracking the moody brain: lifting the mood with ketamineNat Med201016121384138521135850
   PubMed Web of Science ®Google Scholar
• MurroughJWCharneyDSIs there anything really novel on the antidepressant horizon?Curr Psychiatry Rep201214664364922996298
   PubMed Web of Science ®Google Scholar
• TrullasRSkolnickPFunctional antagonists at the NMDA receptor complex exhibit antidepressant actionsEur Pharmacol19901851110
   PubMed Web of Science ®Google Scholar
• LauterbachECDextromethorphan as a potential rapid-acting antidepressantMed Hypotheses201176571771921367535
   PubMed Web of Science ®Google Scholar
• LeeSYChenSLChangYHThe DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorderJ Affect Disord2012138329530022326841
   PubMed Web of Science ®Google Scholar
• ZarateCAJrMathewsDIbrahimLA randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depressionBiol Psychiatry Epub11302012
   Web of Science ®Google Scholar
• PopikPWróbelMNowakGChronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidenceNeuropharmacology200039122278228710974311
   PubMed Web of Science ®Google Scholar
• CraneGECyloserine as an antidepressant agentAm J Psychiatry1959115111025102613637281
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUJavittDCGelfinYControlled trial of D-cy-closerine adjuvant therapy for treatment-resistant major depressive disorderJ Affect Disorder2006931–3239243
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUGelfinGBlochBA randomized add-on trial of high-dose d-cycloserine for treatment-resistant depressionInt J Neuropsychopharmacol201316350150623174090
   PubMed Web of Science ®Google Scholar
• MoskalJRKuoAGWeissCGLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulatorNeuropharmacology20054971077108716051282
   PubMed Web of Science ®Google Scholar
• BurgdorfJZhangXLNicholsonKLGLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effectsNeuropsychopharmacology201338572974223303054
   PubMed Web of Science ®Google Scholar
• MaengSZarateCAJrDuJCellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptorsBiol Psychiatry200863434955217643398
   PubMed Web of Science ®Google Scholar
• LiNLeeBLiuRJmTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonistsScience2010329599495996420724638
   PubMed Web of Science ®Google Scholar
• ZhangLXuTWangSNMDA GluN2B receptors involved in the antidepressant effects of curcumin in the forced swim testProg Neuropsychopharmacol Biol Psychiatry201340121722960607
   PubMed Web of Science ®Google Scholar
• LiNLiuRJDwyerJMGlutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposureBiol Psychiatry201169875476121292242
   PubMed Web of Science ®Google Scholar
• PreskornSHBakerBKolluriSMennitiFSKramsMLandenJWAn innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorderJ Clin Psychopharmacol200828663163719011431
   PubMed Web of Science ®Google Scholar
• IbrahimLDiaz GranadosNJolkovskyLA randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorderJ Clin Psychopharmacol201232455155722722512
   PubMed Web of Science ®Google Scholar
• BobulaBHessGAntidepressant treatments-induced modifications of glutamatergic transmission in rat frontal cortexPharmacol Rep200860686587119211978
   PubMed Web of Science ®Google Scholar
• PittalugaARaiteriLLongordoFAntidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampusNeuropharmacology2007531273617543354
   PubMed Web of Science ®Google Scholar
• HayashiTUmemoriHMishinaMYamamotoTThe AMPA receptor interacts with and signals through the protein tyrosine kinase LynNature1999397671472779892356
   PubMed Web of Science ®Google Scholar
• MackowiakMO’NeillMJHicksCABleakmanDSkolnickPAn AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo studyNeuropharmacology200243111012213254
   PubMed Web of Science ®Google Scholar
• NationsKRBursiRDogteromPMaximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selectionDrugs R D201212312713922852579
   PubMedGoogle Scholar
• NationsKRDogteromPBursiRExamination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trialJ Psychopharmacol201226121525153922954616
   PubMed Web of Science ®Google Scholar
• LiXTizzanoJPGriffeyKClayMLindstromTSkolnickPAntidepressant-like actions of an AMPA receptor potentiator (LY392098)Neuropharmacology20014081028103311406194
   PubMed Web of Science ®Google Scholar
• BaiFLiXClayMLindstromTSkolnickPIntra- and interstrain differences in models of ‘behavioral despair’Pharmacol Biochem Behav2001702–318719211701187
   PubMed Web of Science ®Google Scholar
• LiXWitkinJMNeedABSkolnickPEnhancement of antidepressant potency by a potentiator of AMPA receptorsCell Mol Neurobiol200323341943012825836
   PubMed Web of Science ®Google Scholar
• KnappRJGoldenbergRShuckCAntidepressant activity of memory-enhancing drugs in the reduction of submissive behavior modelEur J Pharmacol20024401273511959085
   PubMed Web of Science ®Google Scholar
• NakamuraKTanakaYAntidepressant-like effects of aniracetam in aged rats and its mode of actionPsychopharmacology2001158220521211702095
   PubMed Web of Science ®Google Scholar
• MannaioniGMarinoMJValentiOTraynelisSFConnPJMetabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell functionJ Neurosci200121165925593411487615
   PubMed Web of Science ®Google Scholar
• AyalaJEChenYBankoJLmGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learningNeuropsychopharmacology20093492057207119295507
   PubMed Web of Science ®Google Scholar
• TatarczyńskaEKlodzińskaAChojnacka-WójcikEPotential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonistBritish J Pharmacol2001132714231430
   PubMed Web of Science ®Google Scholar
• PałuchaABrańskiPSzewczykBWierońskaJMKłakKPilcAPotential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonistPharmacol Biochem Behav200581490190616040106
   PubMed Web of Science ®Google Scholar
• LiXNeedABBaezMWitkinJMMetabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in miceJ Pharmacol Exp Ther2006319125425916803860
   PubMed Web of Science ®Google Scholar
• Pomierny-ChamiołoLPoleszakEPilcANowakGNMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in micePharmacol Rep20106261186119021273676
   PubMed Web of Science ®Google Scholar
• HughesZANealSJSmithDLNegative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depressionNeuropharmacology20136620221422551786
   PubMed Web of Science ®Google Scholar
• BelozertsevaIVKosTPopikPDanyszWBespalovAYAntidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension testsEuropean Neuropsychopharmacol2007173172179
   PubMed Web of Science ®Google Scholar
• Molina-HernándezMTellez-AlcántaraNPPérez-GarcíaJOlivera-LopezJIJaramillo-JaimesMTAntidepressant-like actions of minocycline combined with several glutamate antagonistsProg Neuropsychopharmacol Biol Psychiatry200832238038617933448
   PubMed Web of Science ®Google Scholar
• YoshimizuTShimazakiTItoAChakiSAn mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in ratsPsychopharmacology2006186458759316612616
   PubMed Web of Science ®Google Scholar
• KarasawaJShimazakiTKawashimaNChakiSAMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonistBrain Res200510421929815823257
   PubMed Web of Science ®Google Scholar
• ChakiSYoshikawaRHirotaSMGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activityNeuropharmacology200446445746714975669
   PubMed Web of Science ®Google Scholar
• BespalovAYvan GaalenMMSukhotinaIABehavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depressionEur J Pharmacol20085921–39610218634781
   PubMed Web of Science ®Google Scholar
• CampoBKalinichevMLambengNCharacterization of an mGluR2/3 negative allosteric modulator in rodent models of depressionJ Neurogenet201125415216622091727
   PubMed Web of Science ®Google Scholar
• KennyPJGaspariniFMarkouAGroup II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in ratsJ Pharmacol Exp Ther200330631068107612805481
   PubMed Web of Science ®Google Scholar
• TatarczyńskaEPałuchaASzewczykBChojnacka-WójcikEWierońskaJPilcAAnxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in ratsPol J Pharmacol200254670771012866729
   PubMedGoogle Scholar
• PałuchaATatarczyńskaEBrańskiPGroup III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in ratsNeuropharmacology200446215115914680755
   PubMed Web of Science ®Google Scholar
• StachowiczKKłodzińskaAPalucha-PoniewieraASchannSNeuvillePPilcAThe group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systemsNeuropharmacology200957322723419539634
   PubMed Web of Science ®Google Scholar
• KłakKPałuchaABrańskiPSowaMPilcACombined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in ratsAmino acids200732216917216868652
   PubMed Web of Science ®Google Scholar
• SławińskaAWierońskaJMStachowiczKAnxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu(4) receptorNeuropharmacology20136622523522634361
   PubMed Web of Science ®Google Scholar
• WierońskaJMStachowiczKPałucha-PoniewieraAAcherFBrańskiPPilcAMetabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systemsNeuropharmacology2010597–862763420713068
   PubMed Web of Science ®Google Scholar
• PaluchaAKlakKBranskiPvan der PuttenHFlorPJPilcAActivation of the mGlu7 receptor elicits antidepressant-like effects in micePsychopharmacology2007194455556217622518
   PubMed Web of Science ®Google Scholar
• Pałucha-PoniewieraAPilcAInvolvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension testProg Neuropsychopharmacol Biol Psychiatry201239110210622651960
   PubMed Web of Science ®Google Scholar
• TolliverBKDesantisSMBrownDGPrisciandaroJJBradyKTA randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary reportBipolar Disord2012141546322329472
   PubMed Web of Science ®Google Scholar
• WitteJBentleyKEvinsAEA randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorderJ Clin Psychopharmacol201232678779623131884
   PubMed Web of Science ®Google Scholar
• LangaKMFosterNLLarsonEBMixed dementia: emerging concepts and therapeutic implicationsJAMA2004292232901290815598922
   PubMed Web of Science ®Google Scholar
• QuanMNZhangNWangYYZhangTYangZPossible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat modelNeuroscience2011182889721440043
   PubMed Web of Science ®Google Scholar
• ZarateCAJrSinghJBQuirozJAA double-blind, placebo-controlled study of memantine in the treatment of major depressionAm J Psychiatry2006163115315516390905
   PubMed Web of Science ®Google Scholar
• TsaiGESearching for rational anti N-methyl-D-aspartate treatment for depressionArch Gen Psychiatry200764910991100 author reply 1100–110117768278
   PubMed Web of Science ®Google Scholar
• ColtonCKKongQLaiLIdentification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicityJ Biomol Screen201015665366220508255
   PubMedGoogle Scholar